Search

Your search keyword '"Taxonera C"' showing total 285 results
Start Over Author "Taxonera C" Language english
285 results on '"Taxonera C"'

1. Differential association of two PTPN22 coding variants with Crohn’s disease and ulcerative colitis

Author

Weersma R K, Roberts R L, Gearry R B, Ponsioen C Y, Wijmenga C, van Bodegraven A A, Crusius J B, Barclay M L, Bottini N, López-Nevot M A, Cueto I, Nieto A, Alcain G, Taxonera C, Mendoza J L, Rodrigo L, Cardeña C, van Sommeren S, Gómez-García M, Fransen K, Espino-Paisán L, Diaz-Gallo L M, Urcelay E, Merriman T R, Alizadeh B Z, and Martin J

Subjects
Medicine
Published
2010
Full Text
View/download PDF

2. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

Author

Merino, O., Hernández-Camba, A., Arranz, L., Vera, I., Carpio, D., Calafat, M., Lucendo, A.J., Taxonera, C., Marín, S., Garcia, M.J., Marín, G. Suris, Rodríguez, E. Sánchez, Carbajo, A.Y., De Castro, M.L., Iborra, M., Martin-Cardona, A., Rodríguez-Lago, I., Busquets, D., Bertoletti, F., Ausín, M. Sierra, Tardillo, C., Malaves, J. Huguet, Bujanda, L., Castaño, A., Domènech, E., and Ramos, L.

Published
2022
Full Text
View/download PDF

4. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry

Author

Calafat, M, Mañosa, M, Cañete, F, Panés, J, García Sánchez, V, Calvo, M, Rodríguez-Moranta, F, Taxonera, C, Nos, P, López Sanromán, A, Martín Arranz, M D, Mínguez, M, Gisbert, J P, García-López, S, de Francisco, R, Gomollón, F, Calvet, X, Garcia-Planella, E, Rivero, M, Martínez-Cadilla, J, Argüelles, F, Arias García, L, Cimavilla, M, Zabana, Y, Márquez, L, Gutiérrez, A, Alcaín, G, Martínez Montiel, P, Lázaro, J, Busquets, D, García Sepulcre, M F, Verdejo, C, Bermejo, F, Mora, M, Monfort, D, Romero, P, Velayos, B, Rodríguez, C, Rodríguez, A, Merino, O, Rodríguez-Pescador, A, Bujanda, L, Ber, Y, Vela, M, Roncero, O, Huguet, J M, García-Bosch, O, Barreiro-de-Acosta, M, Madrigal, R E, Ramos, L, Van Domselaar, M, Almela, P, Llaó, J, Lucendo, A J, Muñoz Vilafranca, C, Abad, À, Charro, M, Legido, J, Riera, J, Khorrami, S, Sesé, E, Trapero, A M, and Domènech, E

Published
2018
Full Text
View/download PDF

6. P327 Evolution after a “de-intensification” strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study

Author

Benítez, J.M., Barreiro-de Acosta, M., Chaparro, M., Vázquez, J.M., Iglesias-Flores, E., Tosca, J., García-Planella, E., García-Lpez, S., Taxonera, C., Muñoz-Villafranca, M., Pajares, R., Barrio, J., Arias, L., Nantes, O., Fernández-Salazar, L., Hervías, D., Martín-Arranz, M., Mesonero, F., Moraleja-Yudejo, I., Pineda, J., Argüelles-Arias, F., Huguet, J., Hernández-Martínez, A., Pérez-Calle, J., Leo, E., Merino, O., Van Domselaar, M., Gutiérrez, A., Lorente, R., Castro, M., Algaba, A., Castro, E., Robles-Alonso, V., Ceballos, D., Gmez-García, R., Domínguez, J., Fernández, E., Vega-Lpez, A., Trapero, A., Talavera, A., Royo, V., Gisbert, J.P., and García-Sánchez, V.

Published
2017
Full Text
View/download PDF

8. DOP063 Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients

Author

Taxonera, C., Ponferrada, A., Bermejo, F., Gisbert, J.P., Riestra, S., Saro, C., Cabriada, J.L., Barreiro-de Acosta, M., Barrio, J., Flores, E., Ferrer, I., Hernandez, A., Van Domselaar, M., Olivares, D., Alba, C., Fernández-Salazar, L., Merino, O., Botella, B., Ceballos, D., Moral, I., Peñate, M., and Algaba, A.

Published
2017
Full Text
View/download PDF

10. DOP016 Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study

Author

Chaparro, M., Verreth, A., Lobaton, T., Gravito-Soares, E., Julsgaard, M., Savarino, E., Magro, F., Avni Biron, I., Lpez-Serrano, P., Casanova, M., Gompertz, M., Vitor, S., Arroyo, M., Pugliese, D., Zabana, Y., Vicente, R., Aguas, M., Bar-Gil Shitrit, A., Gutierrez, A., Doherty, G., Fernández-Salazar, L., Martinez Cadilla, J., Huguet, J., OʼToole, A., Stasi, E., Manceñido Marcos, N., Villoria, A., Karmiris, K., Rahier, J., Rodriguez, C., Diz-Lois Palomares, M., Fiorino, G., Benítez, J., Principi, M., Naftali, T., Taxonera, C., Mantzaris, G., Sebkova, L., Iade, B., Lissner, D., Ferrer Bradley, I., Lpez-San Román, A., Marín-Jiménez, I., Merino, O., Sierra, M., Van Domselaar, M., Caprioli, F., Guerra, I., Peixe, P., Piqueras, M., Rodríguez-Lago, I., Ber, Y., Van Hoeve, K., Torres, P., Gravito-Soares, E., Rudbeck-Thomsen, D., Bartolo, O., Peixoto, A., Martín, G., Pérez, J., Garre, A., Donday, M.G., Martín de Carpi, J., and Gisbert, J.P.

Published
2017
Full Text
View/download PDF

11. Health Care Costs of Complex Perianal Fistula in Crohn’s Disease

Author

Chaparro, M., Zanotti, C., Burgueño, P., Vera, I., Bermejo, F., Marín-Jiménez, I., Yela, C., López, P., Martín, M. D., Taxonera, C., Botella, B., Pajares, R., Ponferrada, A., Calvo, M., Algaba, A., Pérez, L., Casis, B., Maté, J., Orofino, J., Lara, N., García-Losa, M., Badia, X., and Gisbert, J. P.

Published
2013
Full Text
View/download PDF

13. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.

Author

Hernández-Camba, A., Arranz, L., Vera, I., Carpio, D., Calafat, M., Lucendo, A.J., Taxonera, C., Marín, S., Garcia, M.J., Marín, G. Suris, Rodríguez, E. Sánchez, Carbajo, A.Y., De Castro, M.L., Iborra, M., Martin-Cardona, A., Rodríguez-Lago, I., Busquets, D., Bertoletti, F., Ausín, M. Sierra, and Tardillo, C.

Abstract

Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments. Our primary objective was to evaluate the effectiveness and safety of MMF in IBD. IBD patients who had received MMF were retrieved from the ENEIDA registry. Clinical activity as per the Harvey‐Bradshaw Index (HBI), partial Mayo score (pMS), physician global assessment (PGA) and C-reactive protein (CRP) were reviewed at baseline, at 3 and 6 months, and at final follow-up. Adverse events and causes of treatment discontinuation were documented. A total of 83 patients were included (66 Crohn's disease, 17 ulcerative colitis), 90% of whom had previously received other immunosuppressants. In 61% of patients systemic steroids were used at initiation of MMF, and in 27.3% biological agents were co-administered with MMF. Overall clinical effectiveness was observed in 64.7% of the population. At the end of treatment, 45.6% and 19.1% of subjects showed remission and clinical response, respectively. MMF treatment was maintained for a median of 28.9 months (IQR: 20.4–37.5). Our study suggests, in the largest cohort to date, that MMF may be an effective alternative to thiopurines and methotrexate in IBD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era

Author

Nunes, T., Etchevers, M. J., Domènech, E., García-Sánchez, V., Ber, Y., Peñalva, M., Merino, O., Nos, P., Garcia-Planella, E., Casbas, A. G., Esteve, M., Samsó, Taxonera C., Huguet, Montoro M., Gisbert, J. P., Arranz, M. D.Martín, García-Sepulcre, M. F., de Acosta, Barreiro- M., Beltrán, B., Suárez, Alcaide N., Gismera, Saro C., Cabriada, J. L., Cañas-Ventura, A., Gomollón, F., and Panés, J.

Published
2013
Full Text
View/download PDF

20. Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

Author

Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Avni Biron I, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Bar-Gil Shitrit A, Gutierrez A, Doherty GA, Fernandez-Salazar L, Martínez Cadilla J, Huguet JM, O'Toole A, Stasi E, Manceñido Marcos N, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Diz-Lois Palomares M, Fiorino G, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Ferrer Bradley I, Lopez-San Roman A, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, Martín-de-Carpi J, and Gisbert JP

Abstract

OBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNF alpha) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNF alpha drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNF alpha medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNF alpha agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. RESULTS: The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNF alpha agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8-1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5-4.3)). CONCLUSIONS: In utero exposure to anti-TNF alpha drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.

Published
2018

23. Polymorphisms in the interleukin-10 gene and relation to phenotype in patients with ulcerative colitis

Author

Mendoza, J. L., Urcelay, E., Lana, R., Martínez, A., Taxonera, C., Concha, E. G. de la, and Díaz-Rubio, M.

Subjects
Interleukin-10 gene, Phenotype, Ulcerative colitis, Colitis ulcerosa, Enfermedad inflamatoria intestinal, Gen de la interleuquina-10, Fenotipo, Inflammatory bowel disease
Abstract

Background and objectives: interleukin-10 (IL-10) has a key role in regulating mucosal inflammation in inflammatory bowel disease. In our population of Spanish ulcerative colitis (UC) patients, we have previously demostrated that two polymorphisms (IL-10.G14 microsatellite allele and homozygous for the -1082G alelle (guanine at position -1082)) in the IL-10 gene were susceptibility markers for disease. No data exist regarding the relationship of these IL-10 polymorphims with phenotypic subpopulations in UC. Therefore, this study sought to examine the contribution of IL-10 polymorphims to phenotypical variability in UC. Material and methods: a cohort of 215 Spanish unrelated patients with UC recruited in a single center was studied. All patients were rigorously phenotyped and followed for at least 3 years (mean time: 11.8 years). The clinical phenotype was established before genotyping. Genotyping was performed using polymerase chain reaction (PCR) assays. Results: patiens with UC included 129 (60%) men and 89 (40%) women. Mean age at diagnosis was 38 years, with a range of 8-83. Disease extent included 127 (59.1%) left-side patients and 88 (40.9%) extensive patients. Neither UC phenotype variable was associated with the presence of susceptibility polymorphims (10G14 microsatellite and -1082G alelle). Conclusions: in Madrid's Spanish population of UC patients, the carrying of the ILG14 microsatellite or -1082G polymorphism in the IL-10 gene was not associated with phenotype of disease. Introducción y objetivo: el gen de la interleuquina 10 (IL-10) tiene un papel clave en la regulación de la inflamación intestinal en la enfermedad inflamatoria intestinal. Recientemente hemos descubierto que dos polimorfismos del gen de la IL-10, el microsatélite IL-10.G14 y ser homocigoto -1082G (guanina en la posición 1082 del gen promotor de la IL-10) son marcadores de susceptibilidad para padecer colitis ulcerosa (CU). No existen datos que demuestren si estos polimorfismos de la IL-10 se correlacionan con las características fenotípicas de la CU. En este trabajo se estudia la relación entre estos polimorfismos del gen de la IL-10 y las diferentes características fenotípicas de la CU. Material y métodos: se estudió una cohorte de 215 pacientes españoles no emparentados que son atendidos habitualmente en la consulta de un único centro hospitalario. Todos los pacientes fueron rigurosamente fenotipados y seguidos clínicamente durante al menos 3 años (tiempo medio de seguimiento 11,8 años). El fenotipaje se realizó antes de conocer el genotipo de los pacientes. El genotipaje se realizó según las técnicas habituales de reacción en cadena de la polimerasa. Resultados: se incluyeron 129 (60%) hombres y 89 (40%) mujeres. La edad media en el momento del diagnóstico fue de 38 años, rango (8-83). La extensión de la CU fue colitis izquierda en 127 (59,1%) pacientes y extensa en 88 (40,9%). Ninguna de la svariables fenotípicas estudiadas se asoció con la presencia o ausencia de los polimorfismos (microsatélite IL10G14 y homocigoto para el alelo -1082G) relacionados con la susceptibilidad a sufrir CU. Conclusiones: en la población española del área de Madrid, los pacientes con CU que son portadores del microsatélite IL10G14 y/o homocigotos -1082G del gen promotor de la IL-10 no se correlacionan con ninguna característica fenotípica de la enfermedad.

Published
2006

25. Diagnostic and treatment recommendations on perianal Crohn's disease

Author

Mendoza, J. L., Taxonera, C., Lana, R., Alba, C., García-Paredes, J., and Díaz-Rubio, M.

Subjects
Treatment, Crohn's disease, Perianal disease, Diagnóstico, Tratamiento, Diagnostic, Enfermedad de Crohn, Enfermedad perianal
Abstract

Treatment of perianal fistulas in Crohn's disease should be defined on an individual basis. A combined medical and surgical approach is the optimal treatment. Adequate management of perianal fistula disease is based on the presence or absence of active proctitis, anatomic location, and fistula type. Furthermore, the presence of perianal abscesses must be ruled out. This evaluation includes digital rectal examination, endoscopy, and examination under anesthesia combined with pelvic magnetic resonance imaging or anorectal endoscopy ultrasonography findings. El tratamiento de la enfermedad fistulosa perianal (EFPA) en la enfermedad de Crohn (EC) debe de ser individualizado y combinar procedimientos médicos y quirúrgicos. Los aspectos clave para un adecuado manejo de la EFPA son determinar la existencia o no de afectación rectal, las características anatómicas y tipo de fístulas, y descartar la existencia de abscesos perianales. Para lograrlo es necesaria una aproximación diagnóstica que incluya inspección y tacto rectal, endoscopia y exploración bajo anestesia combinado con resonancia magnética pélvica o ecografía anal.

Published
2005

27. P651 Identification of new genetic variants related to thiopurine-induced myelotoxicity in inflammatory bowel disease (IBD) patients with normal thiopurines-methyltransferase (TPMT): a genome-wide association study

Author

Chaparro, M., González-Neira, A., Román, M., Pita, G., Cabaleiro, T., Herrero, D., Herráez, B., Alonso, R., Taxonera, C., López-Serrano, P., Martínez-Montiel, P., Vera, I., Bermejo, F., López-San Román, A., Abad-Santos, F., and Gisbert, J.P.

Published
2014
Full Text
View/download PDF

34. Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab.

Author

Medrano, L.M., Taxonera, C., Márquez, A., Barreiro-de Acosta, M., Gómez-García, M., González-Artacho, C., Pérez-Calle, J.L., Bermejo, F., Lopez-Sanromán, A., Martín Arranz, M.D., Gisbert, J.P., Mendoza, J.L., Martín, J., Urcelay, E., and Núñez, C.

Subjects
*INFLAMMATORY bowel disease treatment, *TUMOR necrosis factor receptors, *GENETIC polymorphisms, *CROHN'S disease, *INFLIXIMAB, *JAPANESE people, *PATIENTS, *DISEASES
Abstract

Infliximab (IFX) is a valid treatment for Crohn’s disease (CD), but a relevant percentage of patients do not benefit from this therapy. In the Japanese population, the response to IFX was associated with markers in the TNF receptor superfamily 1A (TNFRSF1A) and 1B (TNFRSF1B) genes. We aimed to replicate the association previously described in the Japanese population and to ascertain the role of TNF receptors as modulators of the response to IFX. We studied 297 white Spanish CD patients with a known response to IFX: 238 responders and 59 primary nonresponders. Four single nucleotide polymorphisms (SNPs) were analyzed: rs767455 in TNFRSF1A and rs1061622, rs1061624, and rs3397 in TNFRSF1B. Comparisons between groups were performed with chi-square tests or the Fisher’s exact test. Different features (sex, age, disease duration, smoking among others) were evaluated as possible confounding factors. No significant association was found between the studied TNFRSF1A polymorphisms and response to IFX. In the TNFRSF1B gene, the haplotype rs1061624_A-rs3397_T was significantly increased in nonresponders: p =0.015, OR=1.78, 95% CI 1.09–2.90; and an increased frequency of rs1061622_G carriers was observed in patients with remission: p =0.033 vs nonresponders and p =0.023 vs patients with a partial response. Our results support a role of TNFRSF1B gene variants in the response to IFX in CD patients. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

35. P670 Identification of new genetic variants related to thiopurineinduced myelotoxicity in inflammatory bowel disease (IBD) patients with normal thiopurine s-methyltransferase (TPMT): a genome-wide association study

Author

Chaparro, M., González-Neira, A., Román, M., Pita, G., Cabaleiro, T., Herrero, D., Herraez, B., Alonso, R., Taxonera, C., López-Serrano, P., Martínez Montiel, P., Vera, I., Bermejo, F., López-San Román, A., Abad-Santos, F., and Gisbert, J.P.

Published
2013
Full Text
View/download PDF

41. Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease.

Author

Casanova, M J, Chaparro, M, Domènech, E, Barreiro-de Acosta, M, Bermejo, F, Iglesias, E, Gomollón, F, Rodrigo, L, Calvet, X, Esteve, M, García-Planella, E, García-López, S, Taxonera, C, Calvo, M, López, M, Ginard, D, Gómez-García, M, Garrido, E, Pérez-Calle, J L, and Beltrán, B

Subjects
INFLAMMATORY bowel disease treatment, HEALTH outcome assessment, PURINES, ANTINEOPLASTIC agents, TUMOR necrosis factors, MEDICATION safety, RETROSPECTIVE studies, PREGNANCY complications
Abstract

OBJECTIVES:The safety of thiopurines and anti-tumor necrosis factor-α (TNF-α) drugs during pregnancy remains controversial, as the experience with these drugs in this situation is limited. Our aim is to assess the safety of thiopurines and anti-TNF-α drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy.METHODS:Retrospective, multicenter study in IBD patients. Pregnancies were classified according to the therapeutic regimens during pregnancy or during the 3 months before the conception: non-exposed group, pregnancies exposed to thiopurines alone (group A), and pregnancies exposed to anti-TNF-α drugs (group B). An unfavorable Global Pregnancy Outcome (GPO) was considered if pregnancy developed with obstetric complications in the mother and in the newborn.RESULTS:A total of 187 pregnancies in the group A, 66 pregnancies in the group B, and 318 pregnancies in the non-exposed group were included. The rate of unfavorable GPO was different among the three groups (31.8% in non-exposed group, 21.9% in group A, and 34.8% in group B), being lower in pregnancies under thiopurines than among non-exposed (P=0.01). The rate of pregnancy complications was similar among the three groups (27.7% in non-exposed, 20.9% in group A, and 30.3% in group B). The rate of neonatal complications was different among the three groups (23.3% in non-exposed group, 13.9% in group A, and 21.2% in group B), being lower in pregnancies under thiopurines than among non-exposed (P=0.01). In the multivariate analysis, the treatment with thiopurines (odds ratio=0.6; 95% confidence interval=0.4-0.9, P=0.02) was the only predictor of favorable GPO, whereas maternal age >35 years at conception was the only predictor of unfavorable GPO. The treatment with anti-TNF-α drugs was not associated with an unfavorable GPO.CONCLUSION:The treatment with thiopurines and anti-TNF-α drugs does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

42. Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial.

Author

Barbero-Villares, A, Jiménez-Ridruejo, J Mendoza, Taxonera, C, López-Sanromán, A, Pajares, R, Bermejo, F, Pérez-Calle, JL, Mendoza, JL, Algaba, A, Moreno-Otero, R, Maté, J, and Gisbert, JP

Subjects
FIBROSIS, LIVER diseases, INFLAMMATORY bowel disease treatment, METHOTREXATE, CROSS-sectional method
Abstract

Background. Methotrexate is an effective treatment for inflammatory bowel disease (IBD). However, long-term treatments have been associated with the development of liver fibrosis. FibroScan® is a noninvasive, safe, and effective technique to evaluate liver fibrosis. Aim. To evaluate the presence of significant liver fibrosis by transient elastography (FibroScan®) in IBD patients treated with methotrexate. Methods. Cross-sectional study including IBD patients treated with methotrexate from different hospitals. Clinical and analytical data, duration of treatment, and cumulative dose of methotrexate were obtained. Liver stiffness was assessed by FibroScan®. The cutoff value for significant liver fibrosis (according to METAVIR) was F ≥2: 7.1 kPa. Results. In the study, 46 patients were included, 30 women (65%), with a mean age of 43 ± 10 years. 31 patients had Crohn's disease (67.4%), 13 ulcerative colitis (28.3%), and 2 indeterminate colitis (4.3%). The mean cumulative dose of methotrexate was 1242 ± 1349 mg, with a mean treatment duration of 21 ± 24 months. The mean value of liver stiffness was 4.7 ± 6.9 kPa. There were 35 patients (76.1%) with F01, 8 patients (17.4%) with F == 2, and 3 patients with F ≥3 (6.5%). There were no differences in liver stiffness depending on sex, age, type of IBD, or cumulative dose of methotrexate. Conclusions. (1) Development of advanced liver fibrosis in IBD patients treated with methotrexate is exceptional. (2) There were no differences in liver stiffness depending on the type of IBD or the cumulative dose of methotrexate. (3) FibroScan® may be potentially useful for evaluation and follow-up of liver fibrosis in methotrexate-treated patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

45. P408 Safety of immunomodulators and anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy

Author

Casanova, M.J., Chaparro, M., Doménech, E., Barreiro-de Acosta, M., Bermejo, F., Iglesias, E., Gomollón, F., Rodrigo, L., Calvet, X., Esteve, M., García-Planella, E., García, S., Taxonera, C., Calvo, M., López, M., Ginard, D., Gómez, M., Garrido, E., Pérez-Calle, J., Beltrán, B., Piqueras, M., Saro, C., Botella, B., Dueñas, C., Ponferrada, A., Mañosa, M., Iglesias, M., Algaba, A., García-Sánchez, V., Maté, J., and Gisbert, J.P.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results